Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HRS9531 Tablets Under Different Dosing Conditions in Healthy Participants
NCT06506175Phase 1Not yet recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Sep 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of HRS9531 in obesity and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Area under the plasma concentration-time curve over the dosing interval. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HRS9531
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06506175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506175.